Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer
Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests under new leadership
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.